On Wednesday April 13, during a press conference organized by the International Federation of the Pharmaceutical Industry (Ifpma), the leader of Pfizer, Albert Bourla, announced that the American company could develop a vaccine to deal with Omicron and other forms of Covid-19 variants, starting in the fall.
“I hope that by the fall, but it is not a certainty, we could have a vaccine”, he tables. Albert Bourla declares “that it is easier to do something only against Omicron”but, on the other hand, “what is scientifically and technically more difficult is to be effective against everything that is known at the moment, so as not to have two different vaccines for different variants”.
The American pharmaceutical giant is carrying out further tests for possible new vaccines and other doses. Albert Bourla specifies that Pfizer will proceed with the sale of their products, “Once we know it’s the best way to go, we’ll seek approval.” It is aimed here particularly at the United States, and at Europe, which remain the largest buyers of vaccine doses.
Should we wonder about the promises of the leader of Pfizer of a future vaccine, when the firm promised a reliability of 95% of the vaccine in 2020? Today, this effectiveness is widely questioned, with a fourth dose of vaccine recommended by the High Authority for Health (HAS) for people over sixty. Ironically referred to as a “second booster dose” by the media mainstreamthis allows a reduction “80% risk of hospitalization, resuscitation, and death”according to Olivier Véran, who relies on the opinion issued by the HAS on March 18.
Read also: Disappointment over the effectiveness of vaccines against Covid-19: the confession of the director of the American CDC
Another question mark: the Paxlovid treatment from the Pfizer laboratory, authorized for early access by the HAS and by the National Agency for the Safety of Medicines and Health Products (ANSM), available in pharmacies for more than two months. Is it an admission of failure to turn away from it so quickly? As a reminder, the government spent a total of 250 million euros for 500,000 boxes purchased, and only 3,500 of them were sold at the end of March…
It should also be noted that these statements by Albert Bourla come when the phase III clinical trials of the first vaccine have still not been completed, and that these same clinical trials have not been particularly rigorous. This was revealed by a survey published by the British Medical Journal on November 2, 2021.
See also: “PfizerGate”? Revelations on clinical trials falsified by the Pfizer – Ventavia – FDA triptych
Finally, while the press mainstream talk about side effects “rares” related to vaccination, remember that doctors continue to warn about the dangers of the Spike protein and excess post-vaccination mortality.
See also: Side effects of vaccines: German scientists throw several stones into the pond
Albert Bourla, awarded the “Business Leadership” prize by Ursula von der Leyen last November, does he confuse speed with haste?